[go: up one dir, main page]

NO20091746L - Nytt difenylazetidinon substituert med piperazin-1-sulfonsyre med forbedrede farmakologiske egenskaper - Google Patents

Nytt difenylazetidinon substituert med piperazin-1-sulfonsyre med forbedrede farmakologiske egenskaper

Info

Publication number
NO20091746L
NO20091746L NO20091746A NO20091746A NO20091746L NO 20091746 L NO20091746 L NO 20091746L NO 20091746 A NO20091746 A NO 20091746A NO 20091746 A NO20091746 A NO 20091746A NO 20091746 L NO20091746 L NO 20091746L
Authority
NO
Norway
Prior art keywords
diphenyllazetidinone
piperazine
substituted
new
sulfonic acid
Prior art date
Application number
NO20091746A
Other languages
English (en)
Inventor
Wendelin Frick
Hubert Heuer
Hans-Ludwig Schaefer
Andreas Lindenschmidt
Gerhard Jaehne
Werner Kramer
Claus-Dieter Graf
Wolfgang Schmider
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20091746L publication Critical patent/NO20091746L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelsen med formel (I) og dens fysiologisk kompatible salter. Forbindelsen er for eksempel egnet som et hypolipidemisk middel.
NO20091746A 2006-11-02 2009-05-04 Nytt difenylazetidinon substituert med piperazin-1-sulfonsyre med forbedrede farmakologiske egenskaper NO20091746L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006051655 2006-11-02
PCT/EP2007/009018 WO2008052658A1 (de) 2006-11-02 2007-10-18 Neues mit piperazin-1-sulfonsäure substituiertes diphenylazetidinon mit verbesserten pharmakologischen eigenschaften

Publications (1)

Publication Number Publication Date
NO20091746L true NO20091746L (no) 2009-07-21

Family

ID=38875004

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091746A NO20091746L (no) 2006-11-02 2009-05-04 Nytt difenylazetidinon substituert med piperazin-1-sulfonsyre med forbedrede farmakologiske egenskaper

Country Status (20)

Country Link
US (1) US20090264402A1 (no)
EP (1) EP2091915A1 (no)
JP (1) JP2010508313A (no)
KR (1) KR20090091120A (no)
CN (1) CN101535249A (no)
AR (1) AR063747A1 (no)
AU (1) AU2007315327A1 (no)
BR (1) BRPI0718052A2 (no)
CA (1) CA2668094A1 (no)
CL (1) CL2007003175A1 (no)
CO (1) CO6160306A2 (no)
IL (1) IL198427A0 (no)
MA (1) MA30819B1 (no)
MX (1) MX2009003823A (no)
NO (1) NO20091746L (no)
RU (1) RU2009120679A (no)
TW (1) TW200826941A (no)
UY (1) UY30682A1 (no)
WO (1) WO2008052658A1 (no)
ZA (1) ZA200901981B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009034388A1 (en) 2007-09-10 2009-03-19 Prosidion Limited Compounds for the treatment of metabolic disorders
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2612669A4 (en) 2010-08-31 2014-05-14 Snu R&Db Foundation USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
HUE045701T2 (hu) 2013-03-13 2020-01-28 Forma Therapeutics Inc 2-Hidroxi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etán-1-on származékok és rokon vegyületek mint zsírsav szintáz (FASN) inhibitorok, rák kezelésére
CN104193731B (zh) * 2014-08-27 2017-03-15 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
CN104513187B (zh) * 2015-01-09 2017-05-31 安润医药科技（苏州）有限公司 依折麦布及其中间体的合成方法
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10227506A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders

Also Published As

Publication number Publication date
AR063747A1 (es) 2009-02-18
KR20090091120A (ko) 2009-08-26
MA30819B1 (fr) 2009-10-01
CL2007003175A1 (es) 2008-05-16
WO2008052658A1 (de) 2008-05-08
UY30682A1 (es) 2008-07-03
JP2010508313A (ja) 2010-03-18
EP2091915A1 (de) 2009-08-26
CA2668094A1 (en) 2008-05-08
CO6160306A2 (es) 2010-05-20
CN101535249A (zh) 2009-09-16
MX2009003823A (es) 2009-05-11
US20090264402A1 (en) 2009-10-22
ZA200901981B (en) 2010-03-31
BRPI0718052A2 (pt) 2015-06-16
RU2009120679A (ru) 2010-12-10
AU2007315327A1 (en) 2008-05-08
TW200826941A (en) 2008-07-01
IL198427A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
NO20091746L (no) Nytt difenylazetidinon substituert med piperazin-1-sulfonsyre med forbedrede farmakologiske egenskaper
NZ592497A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
EA201100503A1 (ru) Глюкозидные производные и их применения
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
EA200901563A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
NO20083717L (no) Pyrrolotriazin-anilin prodrugforbindelser anvendbare som kinaseinhibitorer
EA201592195A1 (ru) Ингибиторы глюкозилцерамидсинтазы
WO2008113559A3 (en) Indolizines and aza-analog derivatives thereof as cns active compounds
MY183312A (en) Pharmaceutical formulation
WO2011056985A3 (en) Substituted heterocyclic compounds
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
EA201100612A1 (ru) Новые производные 2-амидотиадиазола
MY155658A (en) A-isopropylphenyl glucitol compounds as sglti inhibitors
MX2010004669A (es) Proceso para la preparacion de derivados de isoindol asi como tambien un proceso para la preparacion de sus intermediarios.
NO20084301L (no) Tetrahydronaftalenderivater, fremgangsmate for deres fremstilling og anvendelse derav som anti-inflammatoriske midler
EA201071229A1 (ru) Производные иминопиридина и их применение
EA201101147A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
MY149058A (en) N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b
PT2462098E (pt) Processos para a preparação de derivados de ácido 1-(2- halobifenil-4-il)-ciclopropanocarboxílico
EA201000398A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
BR112012017845A2 (pt) novo processo para produção de derivados de benzofenona
EA201001405A1 (ru) Стимуляторы секреции инсулина - производные пиридопиразинонов, способы их получения и их применение для лечения диабета
ATE517900T1 (de) Heptarylen-und octarylentetracarbonsäurediimide und deren herstellung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application